World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
96
Citations
34115
World Ranking
9654
National Ranking
4970

Overview

James L. Gulley is affiliated with the National Institutes of Health in the United States and has a research focus primarily in Medicine, with a specific emphasis on Oncology, Pulmonary and Respiratory Medicine, Immunology, Radiology, Nuclear Medicine and Imaging, and Molecular Biology.

The main topics of their research include Cancer Immunotherapy and Biomarkers, Prostate Cancer Treatment and Research, Immunotherapy and Immune Responses, CAR-T Cell Therapy Research, Cancer Research and Treatments, Prostate Cancer Diagnosis and Treatment, and Radiopharmaceutical Chemistry and Applications.

Gulley's body of work includes contributions to significant recent papers such as:

  • Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce (2020), Journal for ImmunoTherapy of Cancer
  • Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances (2020), Journal for ImmunoTherapy of Cancer
  • Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial (2020), Journal of Thoracic Oncology
  • Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies (2020), Journal for ImmunoTherapy of Cancer
  • Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment (2021), Molecular Oncology

The scientist has collaborated extensively with several coauthors, including:

  • Jeffrey Schlom (107 publications)
  • Ravi A. Madan (76 publications)
  • Renee N. Donahue (74 publications)
  • Fatima Karzai (69 publications)
  • Lisa M. Cordes (65 publications)

James L. Gulley's frequent publication venues demonstrate a focus on clinical oncology and immunotherapy with a significant presence in:

  • Journal of Clinical Oncology (60 publications)
  • Regular and Young Investigator Award Abstracts (39 publications)
  • Journal for ImmunoTherapy of Cancer (38 publications)
  • Annals of Oncology (17 publications)
  • The Oncologist (12 publications)

Best Publications

  • Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

    I. Puzanov;A. Diab;K. Abdallah;C. O. Bingham

  • Androgen Deprivation Therapy for Prostate Cancer

    Nima Sharifi;James L. Gulley;William L. Dahut

  • Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

    Philip W. Kantoff;Thomas J. Schuetz;Brent A. Blumenstein;L. Michael Glode

  • Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.

    Andrea B. Apolo;Jeffrey R. Infante;Ani Balmanoukian;Manish R. Patel

  • Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

    Manish R. Patel;John Ellerton;Jeffrey R. Infante;Manish Agrawal

  • Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.

    Benjamin Boyerinas;Caroline Jochems;Massimo Fantini;Christopher R. Heery

  • Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer

    William L. Dahut;James L. Gulley;Philip M. Arlen;Yinong Liu

  • Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer

    James L. Gulley;Philip M. Arlen;Anne Bastian;Steven Morin

  • Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen–Expressing Carcinomas

    John L. Marshall;James L. Gulley;Philip M. Arlen;Patricia K. Beetham

  • Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.

    Mary L. Disis;Mary L. Disis;Matthew H. Taylor;Karen Kelly;J. Thaddeus Beck

  • Current Landscape of Immunotherapy in Breast Cancer: A Review

    Sylvia Adams;Margaret E. Gatti-Mays;Kevin Kalinsky;Larissa A. Korde

  • Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

    Ravi A Madan;Mahsa Mohebtash;Philip M Arlen;Matteo Vergati

  • Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.

    James L. Gulley;Philip M. Arlen;Ravi A. Madan;Kwong-Yok Tsang

  • A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.

    Philip M Arlen;James L Gulley;Catherine Parker;Lisa Skarupa

  • Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.

    James L. Gulley;Arun Rajan;David R. Spigel;Nicholas Iannotti

  • Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

    Julius Strauss;Christopher R. Heery;Jeffrey Schlom;Ravi A. Madan

  • Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

    Christopher R Heery;Geraldine O'Sullivan-Coyne;Ravi A Madan;Lisa Cordes

  • The role of lineage plasticity in prostate cancer therapy resistance

    Himisha Beltran;Andrew Hruszkewycz;Howard I. Scher;Jeffrey Hildesheim

  • Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

    Wilfred D. Stein;James L. Gulley;Jeff Schlom;Ravi A. Madan

  • Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.

    James Gulley;Alice P. Chen;William Dahut;Philip M. Arlen

Frequent Co-Authors

Jeffrey Schlom
Jeffrey Schlom National Institutes of Health
Philip M. Arlen
Philip M. Arlen National Institutes of Health
Seth M. Steinberg
Seth M. Steinberg National Institutes of Health
William D. Figg
William D. Figg National Institutes of Health
Kwong Y. Tsang
Kwong Y. Tsang National Institutes of Health
James W. Hodge
James W. Hodge National Institutes of Health
Jane B. Trepel
Jane B. Trepel National Institutes of Health
Peter L. Choyke
Peter L. Choyke National Institutes of Health
Baris Turkbey
Baris Turkbey National Institutes of Health
John J. Wright
John J. Wright National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Thinking about alternative or complementary pathways to a traditional medical degree? The healthcare field offers a variety of rewarding online programs that can help you jumpstart your career sooner.

If you're looking for entry into nursing, finding the easiest bsn program to get into can make a difference—especially if you want to avoid highly competitive admissions. In addition, some nursing programs without teas offer a less stressful path by removing standardized test requirements.

Beyond nursing, roles like medical billing and coding are in high demand. Options for financial aid for medical billing and coding can make these programs accessible without breaking the bank.

Those interested in management positions may consider accelerated healthcare programs that let you earn your degree faster and enter the workforce quickly.

With these flexible online degree options, there’s a healthcare career path for every interest and schedule.

Best Scientists Citing James L. Gulley

Trending Scientists

Recently Published Articles